Researchers have successfully neutralized a genetic risk factor found in up to 80% of Alzheimer's patients. The ability to neutralize ApoE4 could help in the development of a vaccine, as well as other therapeutics, for late onset Alzheimer's.
Researchers have identified 216 new gene variants that appear to play a role in the development of late-onset Alzheimer's disease.